News

DermaSensor’s handheld device is awaiting FDA review.

Researchers were unable to determine a definite correlation.

Researchers sought to analyze alopecia areata data in populations historically underrepresented in research.

Phase 3 data of Oleogel-S10 was presented in a late-breaking session at AAD 2023 in New Orleans.

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

Prior use of biologics in patients with plaque psoriasis may not impact the efficacy of risankizumab treatment.

Timber Pharmaceuticals is on its way to developing the first FDA-approved treatment for congenital ichthyosis subtypes.

Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

A pair of phase 3 trials met all primary and secondary endpoints after 48 weeks.

By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.

Sandoz, a Novartis division, expects to launch the new adalimumab biosimilar on July 1, 2023.

The use of tanning beds has become a popular practice in society today, however, it remains undisputed that ultraviolet radiation from natural sunlight and indoor tanning machines increases an individual’s risk of developing skin cancer.

Jack Arbiser, MD, PhD discusses the connection between the skin barrier and anti-aging products.

Results from the phase 3 study were presented at an AAD late-breaking research session.

A key session at the annual meeting will share practical advice and tools to better support you and your patients.

In a world where she practices dermatology, conducts research, and is a super mom, Alina Bridges, DO has nailed down a strategy to not let emails stress her out.

The treatment was deemed effective following a phase 3 study.

Ronda Farah, MD, FAAD, shares her tips and tricks for treating varying types of alopecia.

A review on breast cancer screenings and procedures on the chest is essential to ensure proper gender-affirming care.

Patients with common psychocutaneous diseases, including body dysmorphic disorder (BDD), often refuse a psychiatric referral and instead, present to dermatologists and cosmetic surgeons.

Joshua Zeichner, MD, delivered a boot camp on isotretinoin use at AAD 2023, including an overview of newer formulations of the acne drug that could help counter the common absorption challenges.

What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.

With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.

The impacts of discrimination, harassment, and microaggressions have lasting impact on a clinician’s performance, mental health, and career. Here’s how to create a respectful culture.

Adam Friedman, MD, FAAD, offers highlights from his session at AAD 2023 on how cutaneous dysbiosis plays a role in some common skin conditions.

An AAD 2023 poster presentation reviewed the long-term safety periods of the TruE-AD1 and TRuE-AD2 trials.

“The present and future is narrow-spectrum antibiotics because they enhance antibiotic stewardship, they protect the host microbiome, [and] they reduce antibiotic resistance,” AAD 2023 presenter Christopher Bunick, MD, PhD, said.

A poster presentation from AAD 2023 explored RAPID3 scores to evaluate patient-reported outcomes in routine clinical practice therapy decisions regarding PsA.